Given that mitotane is currently the only approved drug for metastatic ACC and its mechanism remains unclear, the overexpression of TYMS in metastatic ACC may potentially impact the efficacy of mitotane and other chemotherapies, a hypothesis warranting further investigation. The gene discussed is TYMS; the disease is adrenal cortex carcinoma.